KALA BIO, INC. Gain (Loss) on Termination of Lease
KALA BIO, INC. (KALA) reported Gain (Loss) on Termination of Lease of $1.31 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-03.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2023-03-03
- KALA BIO, INC. gain (loss) on termination of lease for fiscal 2021 was $1.31M.
| Period end | Gain (Loss) on Termination of Lease 12 month |
|---|---|
| 2021-12-31 | $1.31M 10-K · filed 2023-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |